- Amedisys delivers another strong quarter despite regulatory shifts and COVID-19-related headwinds.
- Heading into fiscal 2021, the latest guidance indicates the post-COVID-19 recovery is taking shape, although there remains plenty of room for upside surprises.
- Backed by a solid balance sheet and cash generation, the company also looks set for M&A-led growth ahead.
- Shares trade at a premium c. 20x EV/EBITDA multiple on fiscal 2023 numbers, but considering the outlook, there remains plenty of room to grow into the valuation.
For further details see:
Amedisys: Growing Into Its Valuation